Universe Pharmaceuticals INC
UPC Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.24
KIRA · Stoqly’s AI analyst, in plain words
- Universe Pharmaceuticals INC had $17.9B of revenue in fiscal 2025, down 22.4% on the year before. Over five years, revenue changed +257.2% a year on average.
- Its operating margin was −16.3%, up 18.5 pts: of every 100 in sales, about −16 is left after running the business.
- Universe Pharmaceuticals INC lost $3.7B in fiscal 2025.
- Free cash flow was −$5.3B in fiscal 2025, −29.8% of revenue.
- Universe Pharmaceuticals INC has $24.3B more cash than debt.
Market cap
$1.0M
P/E
—
Revenue
$17.9B
Net income
−$3.7B
Free cash flow
−$5.3B
Operating margin
−16.3%
Universe Pharmaceuticals INC in 30 seconds · fiscal 2025
Are sales growing?
−22.4%
No. Sales fell 22.4% last year.
Does it make a profit?
−20.6%
No. It lost money last year.
Does profit turn into cash?
−29.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Universe Pharmaceuticals INC does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 20-F · Jan 29, 2026
- Legal name
- Universe Pharmaceuticals INC
- CIK
- 0001809616
Universe Pharmaceuticals INC · UPC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $48.0M | $40.1M | $32.3B | $23.0B | $17.9B |
| Revenue growth | 56.3% | −16.3% | 80,383.7% | −28.7% | −22.4% |
| Gross margin | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% |
| Operating margin | 28.3% | −17.5% | −12.3% | −34.8% | −16.3% |
| Net income | $11.3M | −$7.9M | −$6.6B | −$8.7B | −$3.7B |
| Net margin | 23.6% | −19.7% | −20.4% | −37.9% | −20.6% |
| Diluted EPS | $3.58 | −$1,309.11 | −$1,089.21 | −$626.96 | −$8.06 |
| Cash | |||||
| Cash from operations | −$2.1M | −$1.3M | $1.1B | −$9.5B | −$5.1B |
| Capital expenditure | $0.4M | $0.1M | $44.2M | $208M | $267M |
| Free cash flow | −$2.5M | −$1.4M | $1.1B | −$9.7B | −$5.3B |
| FCF margin | −5.2% | −3.5% | 3.3% | −42.2% | −29.8% |
| Share count change | −80.2% | −99.8% | 0.0% | 131.7% | 3,179.9% |
| Debt and strength | |||||
| Cash and short-term investments | $21.8M | $5.7B | $5.3B | $29.5B | $33.6B |
| Debt incl. finance leases | $4.3M | $3.9M | $5.5M | $5.9B | $9.3B |
| Shareholders' equity | $47.0M | $35.3B | $28.0B | $45.5B | $56.1B |
| Net debt / EBITDA | −1.2x | — | — | — | — |
| Current ratio | 4.5x | 3.2x | 1.8x | 2.5x | 4.1x |
| Interest coverage | 133.8x | −43.2x | −20.9x | −26.3x | −10.1x |
| Returns and quality | |||||
| Return on capital | 38.1% | −0.0% | −13.8% | −29.0% | −7.2% |
| Return on equity | 33.4% | −0.0% | −20.8% | −23.8% | −7.2% |
| Return on tangible equity | 24.2% | −0.0% | −23.5% | −19.3% | −6.6% |
| Piotroski F-score | 5 | 3 | 4 | 3 | 3 |
| Altman Z'' | 8.3 | — | 1,498.2 | 3.9 | 7.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Universe Pharmaceuticals INC · UPC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.24 a share, the company is worth $1.0M.
Source: SEC EDGAR XBRL filings (CIK 0001809616). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.